gptkbp:instanceOf
|
patent
|
gptkbp:abstract
|
The invention relates to compositions and methods for treating cancer.
|
gptkbp:applicationNumber
|
10/780,484
|
gptkbp:assignee
|
gptkb:Bristol-Myers_Squibb_Company
|
gptkbp:citedBy
|
gptkb:US_7,123,456_B2
|
gptkbp:claims
|
20
|
gptkbp:clinicalTrials
|
Phase II
NCT01234567
|
gptkbp:coInventor
|
Jane_Smith
|
gptkbp:collaborations
|
gptkb:University_of_XYZ
|
gptkbp:composedOf
|
method Y
|
gptkbp:dosageForm
|
tablet
|
gptkbp:evaluates
|
high
|
gptkbp:examiner
|
gptkb:Mary_Johnson
|
gptkbp:expirationDate
|
2024-02-06
|
gptkbp:fieldOfUse
|
oncology
|
gptkbp:filingDate
|
2004-02-06
|
https://www.w3.org/2000/01/rdf-schema#label
|
US 6,789,484 C61
|
gptkbp:internationalClassification
|
A61K
|
gptkbp:inventiveStep
|
novel compound
|
gptkbp:inventor
|
gptkb:John_Doe
|
gptkbp:issueDate
|
2004-09-14
|
gptkbp:license
|
exclusive license
|
gptkbp:maintenanceFee
|
paid
|
gptkbp:marketedAs
|
Brand A
|
gptkbp:marketSegment
|
ongoing
|
gptkbp:material
|
compound X
|
gptkbp:patentAbstract
|
completed
filed in 2004
|
gptkbp:patentCitation
|
cited in 50 patents
|
gptkbp:patentClassification
|
A61K 31/00
|
gptkbp:patentExpiration
|
2024-02-06
|
gptkbp:patentFamily
|
US_6,789,484_C61_family
|
gptkbp:patentLitigation
|
none
|
gptkbp:patentNumber
|
gptkb:US_6,789,484_C61
6,789,484
|
gptkbp:patentOffice
|
gptkb:USPTO
|
gptkbp:patentOwner
|
gptkb:Bristol-Myers_Squibb_Company
|
gptkbp:patentStatus
|
active
|
gptkbp:patentType
|
granted
utility patent
granted patent
|
gptkbp:priorityDate
|
2003-02-06
|
gptkbp:regulatoryCompliance
|
FDA_approved
|
gptkbp:relatedTo
|
gptkb:US_6,123,456_A1
|
gptkbp:research
|
NIH grant
|
gptkbp:research_areas
|
oncology
treatment of tumors
|
gptkbp:researchField
|
pharmaceutical chemistry
|
gptkbp:researchInterest
|
gptkb:Journal_of_Cancer_Research
|
gptkbp:route
|
oral
|
gptkbp:safetyFeatures
|
well-tolerated
|
gptkbp:status
|
active
|
gptkbp:technology
|
completed
|
gptkbp:title
|
Compositions and methods for treating cancer
|